Premium
Suppression of experimental autoimmune encephalomyelitis by sulfasalazine
Author(s) -
Prosiegel M.,
Neu I.,
Vogl S.,
Hoffmann G.,
Wildfeuer A.,
RuhenstrothBauer G.
Publication year - 1990
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1990.tb00973.x
Subject(s) - sulfasalazine , rheumatoid arthritis , medicine , leukotriene c4 , experimental autoimmune encephalomyelitis , multiple sclerosis , leukotriene , pathogenesis , immunology , leukotriene b4 , encephalomyelitis , inflammatory bowel disease , guinea pig , leukotriene d4 , inflammation , arachidonic acid , eicosanoid , autoimmune disease , pharmacology , ulcerative colitis , disease , chemistry , enzyme , antibody , biochemistry , asthma
It has recently been suggested that the sulfidopeptide leukotriene C 4 (LTC 4 ), a 5‐lipoxygenase product of the arachidonic acid metabolism and one of the most potent mediators of vascular permeability, might be involved in the pathogenesis of experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Subsequently, 20 guinea pigs with EAE were treated with sulfasalazine, a substance with a proved leukotriene inhibiting effect, which has previously been described as exerting beneficial effects in patients with inflammatory bowel disease and rheumatoid arthritis. The sulfasalazine‐treated guinea pigs showed a significantly better clinical outcome, as well as a significantly lower histological inflammation score compared with 19 controls.